Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers.

Persson G, Ankerst J, Gillen M, Bengtsson T, Thorsson L.

Curr Med Res Opin. 2008 May;24(5):1511-7. doi: 10.1185/030079908X297312 . Epub 2008 Apr 16.

PMID:
18419877
2.

Evidence of the in vivo esterification of budesonide in human airways.

van den Brink KI, Boorsma M, Staal-van den Brekel AJ, Edsbäcker S, Wouters EF, Thorsson L.

Br J Clin Pharmacol. 2008 Jul;66(1):27-35. doi: 10.1111/j.1365-2125.2008.03164.x. Epub 2008 Apr 1.

3.

Exposure of infants to budesonide through breast milk of asthmatic mothers.

Fält A, Bengtsson T, Kennedy BM, Gyllenberg A, Lindberg B, Thorsson L, Stråndgarden K.

J Allergy Clin Immunol. 2007 Oct;120(4):798-802. Epub 2007 Sep 7.

PMID:
17825891
4.

Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis.

Ahlström Emanuelsson C, Andersson M, Persson CG, Thorsson L, Greiff L.

Respir Med. 2007 Jun;101(6):1106-12. Epub 2007 Jan 9.

5.

Degree of throat deposition can explain the variability in lung deposition of inhaled drugs.

Borgström L, Olsson B, Thorsson L.

J Aerosol Med. 2006 Winter;19(4):473-83.

PMID:
17196076
6.

Idealhalers or realhalers? A comparison of Diskus and Turbuhaler.

Borgström L, Asking L, Thorsson L.

Int J Clin Pract. 2005 Dec;59(12):1488-95. Review.

PMID:
16351685
7.
8.

Drug disposition analysis: a comparison between budesonide and fluticasone.

Källén A, Thorsson L.

J Pharmacokinet Pharmacodyn. 2003 Aug;30(4):239-56.

PMID:
14650373
9.

Systemic availability and lung deposition of budesonide via three different nebulizers in adults.

Dahlström K, Thorsson L, Larsson P, Nikander K.

Ann Allergy Asthma Immunol. 2003 Feb;90(2):226-32.

PMID:
12602671
10.

Systemic availability of Rhinocort Aqua (budesonide) nasal spray: importance of formulation and definition of delivered dose.

O'Dowd L, Thorsson L, Edsbacker S.

J Allergy Clin Immunol. 2002 Jun;109(6):1037; author reply 1037-8. No abstract available.

PMID:
12063539
11.

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler.

Thorsson L, Edsbäcker S, Källén A, Löfdahl CG.

Br J Clin Pharmacol. 2001 Nov;52(5):529-38.

12.
13.

Fluticasone and asthma.

Edsbäcker S, Thorsson L.

Lancet. 2001 Mar 10;357(9258):804. No abstract available.

PMID:
11253999
14.

Lung deposition of inhaled drugs increases with age.

Onhøj J, Thorsson L, Bisgaard H.

Am J Respir Crit Care Med. 2000 Nov;162(5):1819-22.

PMID:
11069819
15.
17.
18.

The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients.

Kenyon CJ, Thorsson L, Borgström L, Newman SP.

Eur Respir J. 1998 Mar;11(3):606-10.

19.

Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study.

Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Källén A.

J Allergy Clin Immunol. 1998 Mar;101(3):312-9.

PMID:
9525445
20.

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.

Thorsson L, Dahlström K, Edsbäcker S, Källén A, Paulson J, Wirén JE.

Br J Clin Pharmacol. 1997 Feb;43(2):155-61.

21.

Influence of inhaler systems on systemic availability, with focus on inhaled corticosteroids.

Thorsson L.

J Aerosol Med. 1995 Sep;8 Suppl 3:S29-36; discussion S37. Review.

PMID:
10157896
22.

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.

Thorsson L, Edsbäcker S, Conradson TB.

Eur Respir J. 1994 Oct;7(10):1839-44.

23.

Nasal distribution of budesonide inhaled via a powder inhaler.

Thorsson L, Newman SP, Weisz A, Trofast E, Morén F.

Rhinology. 1993 Mar;31(1):7-10.

PMID:
8321983
24.

Supplemental Content

Loading ...
Support Center